Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis

This study has been withdrawn prior to enrollment.
(Lack of funds)
Information provided by (Responsible Party):
Institute of Liver and Biliary Sciences, India Identifier:
First received: June 28, 2011
Last updated: October 8, 2015
Last verified: July 2012
120 patients of biopsy proven NASH will be randomized into two groups. Cases group will receive combination of pentoxiphylline and Vitamin E, and control group will receive only Vitamin E.

Condition Intervention Phase
Non Alcoholic Steatohepatitis
Drug: pentoxiphylline and Vitamin E
Drug: Vitamin E
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis

Resource links provided by NLM:

Further study details as provided by Institute of Liver and Biliary Sciences, India:

Primary Outcome Measures:
  • histological outcome in the form of improvement or non- progression in hepatocyte injury and fibrosis (NAS score). [ Time Frame: 3 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Response in form of anthropometry , HOMA-IR, fasting lipid profiles, biochemical response in form of normalization of ALT and AST levels and reduction in uric [ Time Frame: 3 Months ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: July 2011
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: pentoxiphylline and Vitamin E Drug: pentoxiphylline and Vitamin E
Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
Active Comparator: Vitamin E Drug: Vitamin E
Patients in control group will receive vitamin E 800 IU/day

Detailed Description:

The investigators plan to randomise 120 patients of biopsy proven NASH into cases and control groups.

Baseline investigations:

Clinical characteristics

  • Age
  • Gender
  • Anthropometry (BMI, waist circumference, waist- hip ratio, triceps skin fold thickness, mid arm circumference)
  • Alcohol intake should be nil

Laboratory characteristics

  • Hemogram, INR, KFT
  • LFT (especially ALT, GGT) , APRI (AST to platelet ratio)
  • Fasting Lipid Profile
  • Other possible etiologies of liver disease (viral markers, ferritin, ANA, IgG, ceruloplasmin )
  • HOMA-IR (II)
  • Serum uric acid levels Liver stiffness
  • Fibroscan
  • MR elastography Radiological characteristics
  • USG abdomen Variceal status by UGI endoscopy Alpha fetoprotein Pro- inflammatory markers
  • TNF-alpha, IL-6, adiponectin, leptin and osteopontin Liver biopsy and NAS score

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 70 years
  • Persistently abnormal ALT >1.2 times upper limit of normal
  • Histological evidence of NASH/cirrhosis on liver biopsy. ( The minimal criteria for diagnosis of NASH included the presence of lobular inflammation and either ballooning of cells or perisinusoidal or pericellular fibrosis in Zone 3 of the hepatic acinus)

Exclusion Criteria:

  • A known case of Type 2 diabetes mellitus on treatment
  • Alcohol intake of more than 40gm / week
  • If they had evidence of cirrhosis with significant portal hypertension
  • Ongoing total parenteral nutrition/ jejunal-ileal bypass
  • Other known liver disease (Hepatitis A to E, autoimmune liver disease, Wilson's disease, alpha 1 antitrypsin deficiency and hemochromatosis)
  • Medication like estrogens, amiodarone, MTx, tamoxifen, ATT
  • Pregnancy or lactation
  • Hypersensitivity to methylxanthines (e.g., caffeine, theophylline, theobromine )
  • Recent retinal/cerebral hemorrhage
  • Acute myocardial infarction or severe cardiac arrhythmias
  • Impaired renal function
  • Hypothyroidism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01384578

Institute of liver and Biliary Sciences
New Delhi, Delhi, India, 110070
Sponsors and Collaborators
Institute of Liver and Biliary Sciences, India
Study Director: Shiv Kumar Sarin, MD,DM Institute of Liver & Biliary Sciences (ILBS)
  More Information

Responsible Party: Institute of Liver and Biliary Sciences, India Identifier: NCT01384578     History of Changes
Other Study ID Numbers: ILBS-NASH-02 
Study First Received: June 28, 2011
Last Updated: October 8, 2015
Health Authority: India: Ministry of Health

Additional relevant MeSH terms:
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases
Liver Diseases
Vitamin E
Enzyme Inhibitors
Free Radical Scavengers
Growth Substances
Molecular Mechanisms of Pharmacological Action
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Protective Agents
Radiation-Protective Agents
Vasodilator Agents processed this record on May 24, 2016